Sign up to save your podcasts
Or
Share The VESALIUS-CV Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The VESALIUS-CV Trial
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
View all episodes
By TCTMD
4
22 ratings
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
More shows like Talking Points
View all
NEJM This Week
319 Listeners
JAMA Clinical Reviews
502 Listeners
JACC This Week
162 Listeners
This Week in Cardiology
896 Listeners
Heart Sounds
12 Listeners
The Curbsiders Internal Medicine Podcast
3,378 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
136 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
736 Listeners
Annals On Call Podcast
196 Listeners
JAMA Medical News
91 Listeners
The Clinical Problem Solvers
519 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
377 Listeners
Cardionerds: A Cardiology Podcast
436 Listeners
Critical Care Time
269 Listeners